Research digest — GHRH analogue + GH secretagogue
CJC-1295 Ipamorelin: what the two-peptide stack has, and has not, been studied to do.
Two peptides on two pathways, paired for a bigger growth-hormone pulse. Here is what each half's literature shows, where the with-DAC and no-DAC versions diverge, and why the combination itself has never been tested.
The short version
CJC-1295 Ipamorelin is not one drug — it is two research peptides used together. CJC-1295 is a long-acting copy of a natural signal (growth-hormone-releasing hormone, the body's own "make more growth hormone" message). Ipamorelin is a separate peptide that flips a different switch on the same pituitary cells (the ghrelin receptor, the one tied to hunger). Because they push on two different levers at once, the pair is meant to release a larger pulse of growth hormone than either alone. In healthy adults, CJC-1295 alone raised growth hormone and IGF-1 — the liver hormone that carries out most of growth hormone's effects — for days [1]. The honest catch: the fixed two-peptide blend has never been tested in a controlled human trial, so every "the stack does X" claim is borrowed from each peptide's own studies. People in research-use circles report deeper sleep, faster recovery, more appetite, and some downsides — the full picture, including the downsides, is on the effects page.
Two pathways, one larger pulse
Growth hormone is released in bursts, not a steady stream, and three signals set the rhythm: GHRH turns it up, somatostatin turns it down, and ghrelin nudges it up through a separate channel. CJC-1295 is a tetra-substituted GHRH analogue — a redesigned copy of the natural releasing hormone built to survive longer in the blood. Ipamorelin is a selective ghrelin-receptor agonist (a GHRP, or growth-hormone-releasing peptide), meaning it triggers the ghrelin switch without the off-target baggage of older peptides in its class.
The rationale for combining them is decades old. In normal men, a GHRP paired with GHRH released growth hormone synergistically — more than the sum of the two given alone — with the two acting through independent mechanisms [3]. At the receptor level, co-activating the cloned GHRH and ghrelin receptors in transfected cells produced roughly twice the cAMP signal of GHRH alone [4]. That supra-additive math is the entire case for CJC-1295 Ipamorelin research as a pairing.
What CJC-1295 actually did in people
The strongest human data belongs to CJC-1295 with DAC. A single subcutaneous dose raised mean plasma growth hormone two- to ten-fold for six days or more and IGF-1 1.5- to three-fold for nine to eleven days in healthy adults aged 21 to 61; with repeated dosing, IGF-1 stayed above baseline for up to 28 days [1]. That multi-day profile comes from the DAC (Drug Affinity Complex) — a chemical handle that covalently bonds the peptide to albumin in the blood, stretching its half-life from minutes to days [5].
Ipamorelin's human pharmacology is thinner. It was defined as the first selective growth-hormone secretagogue: in animals it released growth hormone as effectively as GHRP-6 but, unlike GHRP-6 and GHRP-2, did not raise the stress hormones ACTH or cortisol above GHRH-stimulated levels, even at doses more than 200 times the amount needed for a half-maximal growth-hormone response [2]. Its appeal is that selectivity. What it lacks is a published human pharmacokinetic study.
The half-life split that the labels hide
"CJC-1295" names two very different molecules, and the distinction drives most of the confusion in this space. CJC-1295 with DAC carries the albumin-binding complex and acts for days [1][5]. CJC-1295 without DAC — sold as Mod GRF (1-29) — omits that complex and behaves like native releasing hormone, cleared in roughly 30 minutes by the enzyme DPP-IV. Pairing ipamorelin, which produces a single short pulse cleared within hours [2], with the multi-day DAC version is a fundamentally different exposure profile than pairing it with the short Mod GRF (1-29). The literature that justifies the synergy used short pulses, not days-long continuous drive [3]. The vs-sermorelin comparison and the dosage page work through what that means.
What this site is, and is not
This is an editorial digest of the published research on CJC-1295 Ipamorelin — the mechanism, the pharmacokinetics, the safety reviews, and the regulatory record, each quantitative claim cited to a study. Neither peptide is approved by the FDA for any human use, and both are prohibited at all times in sport under WADA Section S2 (peptide hormones and growth factors) [6]. The "rx" in this domain's name is editorial framing, not a pharmacy — nothing here is dosed, prescribed, or sold. The CJC-1295 Ipamorelin references list every source.